Placental Lactogen Sf9, Human
Sf9, Baculovirus cells.
Chorionic Somatomammotropin Hormone 1, CSH1, Choriomammotropin, Lactogen, CSH2, PL, CSA, CSMT, FLJ75407
Greater than 90.0% as determined by SDS-PAGE.
Description
Placental Lactogen Human produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 197 amino acids (27-217 aa) and having a molecular mass of 23.1kDa.
Placental Lactogen is fused to a 6 amino acid His tag at C-terminus and purified by proprietary chromatographic techniques.
Product Specs
Chorionic Somatomammotropin Hormone 1, CSH1, Choriomammotropin, Lactogen, CSH2, PL, CSA, CSMT, FLJ75407
Sf9, Baculovirus cells.
VQTVPLSRLF DHAMLQAHRA HQLAIDTYQE FEETYIPKDQ KYSFLHDSQT SFCFSDSIPT PSNMEETQQK SNLELLRISL LLIESWLEPV RFLRSMFANN LVYDTSDSDD YHLLKDLEEG IQTLMGRLED GSRRTGQILK QTYSKFDTNS HNHDALLKNY GLLYCFRKDM DKVETFLRMV QCRSVEGSCG FHHHHHH
Product Science Overview
Placental lactogen, also known as human chorionic somatomammotropin, is a polypeptide hormone produced by the placenta during pregnancy. It plays a crucial role in modifying the metabolic state of the mother to facilitate energy supply to the fetus. The recombinant form of this hormone, produced using the Sf9 insect cell expression system, has been instrumental in research and therapeutic applications.
Human placental lactogen (hPL) is a member of the prolactin/growth hormone family and shares structural similarities with human growth hormone. It is composed of a single chain of 191 amino acids, linked by two disulfide bonds, and has a molecular mass of approximately 22,125 Da . The recombinant form of hPL is produced using the Sf9 insect cell expression system, which involves the insertion of the hPL gene into the baculovirus vector, followed by infection of the Sf9 cells. This system is advantageous due to its high expression levels and proper post-translational modifications.
hPL is secreted by the syncytiotrophoblast cells of the placenta and is present in the maternal serum during pregnancy. Its levels increase progressively with the growth of the fetus and placenta, reaching a peak near term. The primary function of hPL is to regulate the metabolic state of the mother, ensuring an adequate supply of nutrients to the fetus. It decreases maternal insulin sensitivity, leading to increased blood glucose levels, and promotes lipolysis, releasing free fatty acids for maternal energy use .
The primary role of hPL is to support fetal growth by modulating maternal metabolism. It decreases maternal glucose utilization, ensuring a steady supply of glucose to the fetus. Additionally, hPL promotes the mobilization of free fatty acids from adipose tissue, providing an alternative energy source for the mother. These metabolic adaptations are crucial for maintaining fetal nutrition, especially during periods of maternal malnutrition .
hPL exerts its effects by binding to the prolactin receptor and, to a lesser extent, the growth hormone receptor. It mimics the action of prolactin in various tissues, including the mammary glands, where it promotes lactogenesis. However, its role in human lactation remains unclear. hPL also influences the maternal immune system, contributing to the immune tolerance of the fetus .
The expression of hPL is regulated at multiple levels, including gene transcription, mRNA stability, and protein secretion. Various factors, such as placental growth, maternal nutritional status, and hormonal signals, influence hPL production. The precise regulatory mechanisms are complex and involve interactions between different signaling pathways .
